Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company. It is a subsidiary of Hoffmann-La Roche, which owned 62% of the firm as of June 30, 2014. Chugai focuses on biopharmaceutical and therapeutic antibody research, development, commercialization, production, import, and export. Furthermore, as a competitive advantage, the Japanese pharmaceutical company promotes its antibody engineering technology, personalized healthcare, and enhanced patient-centric solutions. Chugai has dominated the Japanese cancer market for over a decade and is presently developing treatments for bone and joint illnesses as well as renal ailments.

The company provides products for the treatment of a variety of therapeutic areas, including cancer, bone and joint illnesses, renal diseases, immunological disorders, and infectious diseases, among others. It also provides medications to help with kidney, liver, and other organ transplants. It also has a number of product candidates in the pipeline. The company sells pharmaceutical items in North America, Europe, and Asia through its network of subsidiaries.

Founded: 1943
Headquarters: Tokyo, Japan
Official website: https://www.chugai-pharm.co.jp/